Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat. Med., 9, 279, 10.1038/nm827

Brentjens, 2007, Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts, Clin. Cancer Res., 13, 5426, 10.1158/1078-0432.CCR-07-0674

Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci. Transl. Med., 5, 177ra38, 10.1126/scitranslmed.3005930

Brown, 2016, Regression of glioblastoma after chimeric antigen receptor T-cell therapy, N. Engl. J. Med., 375, 2561, 10.1056/NEJMoa1610497

Chekmasova, 2010, Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen, Clin. Cancer Res., 16, 3594, 10.1158/1078-0432.CCR-10-0192

Cherkassky, 2016, Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition, J. Clin. Invest., 126, 3130, 10.1172/JCI83092

Chmielewski, 2017, CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors, Cell Rep., 21, 3205, 10.1016/j.celrep.2017.11.063

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6, 224ra25, 10.1126/scitranslmed.3008226

Feng, 2017, Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma, J. Hematol. Oncol., 10, 4, 10.1186/s13045-016-0378-7

Gajewski, 2006, Immune resistance orchestrated by the tumor microenvironment, Immunol. Rev., 213, 131, 10.1111/j.1600-065X.2006.00442.x

Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, 127, 2406, 10.1182/blood-2015-08-665547

Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208

Gong, 1999, Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen, Neoplasia, 1, 123, 10.1038/sj.neo.7900018

Hart, 2011, IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer, Front. Immunol., 2, 29, 10.3389/fimmu.2011.00029

Hu, 2017, Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18, Cell Rep., 20, 3025, 10.1016/j.celrep.2017.09.002

Jackson, 2016, Driving CAR T-cells forward, Nat. Rev. Clin. Oncol., 13, 370, 10.1038/nrclinonc.2016.36

John, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin. Cancer Res., 19, 5636, 10.1158/1078-0432.CCR-13-0458

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3, 95ra73, 10.1126/scitranslmed.3002842

Khan, 2015, Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer, Oncotarget, 6, 11310, 10.18632/oncotarget.3597

Koneru, 2015, IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo, OncoImmunology, 4, e994446, 10.4161/2162402X.2014.994446

Krevvata, 2014, Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts, Blood, 124, 2834, 10.1182/blood-2013-07-517219

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449

Mantovani, 2002, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol., 23, 549, 10.1016/S1471-4906(02)02302-5

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci. Transl. Med., 9, eaaa0984, 10.1126/scitranslmed.aaa0984

Pegram, 2012, Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning, Blood, 119, 4133, 10.1182/blood-2011-12-400044

Pegram, 2015, IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia, Leukemia, 29, 415, 10.1038/leu.2014.215

Richards, 2006, Tumor growth impedes natural-killer-cell maturation in the bone marrow, Blood, 108, 246, 10.1182/blood-2005-11-4535

Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov., 5, 1282, 10.1158/2159-8290.CD-15-1020

Spitzer, 2015, IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system, Science, 349, 1259425, 10.1126/science.1259425

Wang, 2015, Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia, Mol. Ther., 23, 184, 10.1038/mt.2014.164

Yuan, 2015, Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression, Sci. Rep., 5, 14273, 10.1038/srep14273

Zunder, 2015, Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm, Nat. Protoc., 10, 316, 10.1038/nprot.2015.020